Clinical Trials Directory

Trials / Completed

CompletedNCT01813305

CSTC1 for Diabetic Foot Ulcers Phase II Study

A Randomized,Double-Blind,Vehicle-controlled,Parallel,Phase II Study to Evaluate Efficacy and Safety of CSTC1 in Patient With Diabetic Foot Ulcers

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
124 (actual)
Sponsor
Charsire Biotechnology Corp. · Industry
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

The objective of this study is to evaluate the efficacy and safety of CSTC1 in patient with diabetic foot ulcers.

Detailed description

This study was designed as a randomized, double-blind, vehicle-controlled, multiple-center, and parallel trial to evaluate the efficacy and safety of CSTC1 in patients with diabetic foot ulcers (DFU). In each study site, eligible patients were randomized in a 4:1 ratio to receive either one of the topical applications of CSTC1 or CSTC1 matched vehicle, topical application on target diabetic foot ulcer (DFU), 2 times daily. The treatment duration for each subject was 12 weeks or up to confirmed complete ulcer closure, whichever comes first. That was, subjects would receive treatment for at most 12 weeks, which consists of 8 visits located at weeks 1, 2, 3, 4, 6, 8, 10, and 12. Subjects who achieved confirmed complete ulcer closure during the treatment period would be arranged for a 12 week post-treatment follow-up. Subjects failed to achieve complete ulcer closure at week-12 visit would be arranged for 4 weeks of safety follow-up. If confirmation of complete ulcer closure was reached at a week-14 visit, the subject would continue the post-treatment follow-up visit until week-24 visit. Otherwise, the subject would be arranged for safety follow-up until week-16 visit.

Conditions

Interventions

TypeNameDescription
DRUGCSTC1vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof
DRUGCSTC1 Matched vehicle

Timeline

Start date
2014-07-09
Primary completion
2020-01-07
Completion
2020-01-07
First posted
2013-03-18
Last updated
2022-04-12
Results posted
2022-04-12

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT01813305. Inclusion in this directory is not an endorsement.